Makers of active pharmaceutical ingredients need to work on improving the integrity of their manufacturing data, if recent US Food and Drug Administration warning letters are any indication.
US FDA Says Data Integrity Remains Challenging For API Manufacturers
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
